Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E22.18 EPS (ttm)2.36 Insider Own0.10% Shs Outstand1.64B Perf Week-13.09%
Market Cap85.79B Forward P/E13.67 EPS next Y3.83 Insider Trans-8.78% Shs Float1.63B Perf Month-20.84%
Income3.90B PEG1.87 EPS next Q0.83 Inst Own72.50% Short Float0.68% Perf Quarter-15.44%
Sales20.78B P/S4.13 EPS this Y-10.90% Inst Trans0.00% Short Ratio1.28 Perf Half Y-17.83%
Book/sh7.18 P/B7.28 EPS next Y17.36% ROA3.00% Target Price65.50 Perf Year-1.19%
Cash/sh4.15 P/C12.59 EPS next 5Y11.87% ROE7.20% 52W Range51.56 - 70.05 Perf YTD-14.65%
Dividend1.60 P/FCF52.21 EPS past 5Y15.30% ROI20.20% 52W High-26.21% Beta0.95
Dividend %3.06% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin71.50% 52W Low0.25% ATR1.84
Employees23700 Current Ratio1.60 Sales Q/Q3.90% Oper. Margin25.20% RSI (14)17.50 Volatility4.33% 3.01%
OptionableYes Debt/Eq0.68 EPS Q/Q-34.60% Profit Margin4.80% Rel Volume2.01 Prev Close52.30
ShortableYes LT Debt/Eq0.59 EarningsApr 26 BMO Payout261.40% Avg Volume8.70M Price51.69
Recom2.60 SMA20-14.76% SMA50-19.07% SMA200-16.03% Volume9,078,500 Change-1.17%
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Apr-18-18 04:15PM  U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review Business Wire
12:41PM  Trader adding to this beaten pharma stock CNBC Videos
07:45AM  The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential ACCESSWIRE
Apr-17-18 02:29PM  Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It Bloomberg
02:16PM  One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings Benzinga
12:13PM  Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY) Simply Wall St.
10:52AM  Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better Zacks
10:44AM  MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade Yahoo Finance Video
08:34AM  Stocks Push Forward As Fears of War Diminish InvestorPlace
08:20AM  Todays Research Reports on Trending Tickers: Bristol-Myers Squibb and TESARO ACCESSWIRE
06:58AM  Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets MarketWatch
06:32AM  Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets Motley Fool
12:45AM  [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal
Apr-16-18 04:57PM  What Happened in the Stock Market Today Motley Fool -7.79%
04:41PM  Bristol-Myers Partners With Janssen on Anticlotting Therapy Bloomberg
04:32PM  The Biggest Movers: J.B. Hunt Jumps; Bristol Myers Drops Barrons.com
04:26PM  Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests Investor's Business Daily
04:15PM  Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy Business Wire
04:03PM  In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Business Wire
02:09PM  Merck extends lead over Bristol-Myers in lung cancer race CNBC Videos
01:33PM  Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg Video
01:33PM  Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg
01:18PM  Merck to move scientists and money toward promising cancer drug American City Business Journals
12:52PM  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Business Wire
12:05PM  [$$] Bristol-Myers Has Farther to Fall The Wall Street Journal
11:35AM  Survival data boosts Merck's Keytruda lead in lung cancer Reuters
11:17AM  Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data TheStreet.com
10:37AM  Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo Zacks
10:12AM  Merck shares rise after beating rivals' lung cancer results MarketWatch
09:38AM  Bristol-Myers and Merck meet cancer study goals CNBC Videos
09:30AM  [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal
09:30AM  Merck Keeps Edge Over Bristol-Myers In Cancer Duel Forbes
09:30AM  Merck drug results suggest it will extend its lead in lung cancer; Bristol-Myers shares drop CNBC
09:30AM  Merck Cements Lead in Lung Cancer With Bristol-Myers Fizzling Bloomberg
09:24AM  Bristol-Myers says cancer drug combo reduces death risk Reuters
09:19AM  Bristol-Myers Says Lung Cancer Drug Combination Met Trial Goal Bloomberg
09:05AM  Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB) Business Wire
07:10AM  Stock Market Futures Rally After Syria Mission 'Accomplished'; These 5 S&P 500 Stocks Have Big News Investor's Business Daily
Apr-15-18 09:30PM  [$$] Merck lung cancer trial boosts immunotherapy hopes Financial Times
Apr-13-18 04:51PM  Illumina shares advance on Bristol-Myers cancer drug collaboration MarketWatch
04:34PM  Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC) Business Wire
04:15PM  Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibbs Oncology Immunotherapies Business Wire
02:19PM  Lung cancer battle brews CNBC Videos
11:47AM  Bristol-Myers Collaborates With Harvard Fibrosis Network Zacks
07:22AM  Drugmakers vie for dominance in lung cancer treatment CNBC Videos
Apr-12-18 04:44PM  Intel and Costco rise while Bed Bath & Beyond tumbles Associated Press
03:30PM  Pfizer's Deal Potential Doesn't Stop at Bristol-Myers Bloomberg
10:37AM  Nektar Starts Phase I/II Combo for Advanced Solid Tumors Zacks
06:59AM  Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration Business Wire
Apr-11-18 07:17PM  Syria Crisis Doesn't Affect Bristol-Myers (It Could Help Amazon): Cramer Insider TheStreet.com
07:01PM  Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good TheStreet.com
07:01PM  Jim Cramer: Fed Minutes and Oil Hit the Market TheStreet.com
Apr-10-18 11:58AM  3 Reasons to Be Bullish on Merck & Co., Inc. Stock InvestorPlace
11:00AM  DEADLINE TODAY: The Klein Law Firm Reminds Investors of a Class Action on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY) ACCESSWIRE
10:16AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Bristol-Myers Squibb Company (BMY) and Lead Plaintiff Deadline: April 10, 2018 ACCESSWIRE
07:34AM  Novartis and Other Drug Stocks With FDA Catalysts in April Zacks
Apr-09-18 04:24PM  AveXis and Western Digital jump; Campbell Soup falls Associated Press
12:20PM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Bristol-Myers Squibb Company of a Class Action and a Lead Plaintiff Deadline of April 10, 2018 - BMY ACCESSWIRE
12:10PM  Novartis expands with acquisition, Viacom/CBS talks continue, Tesla issues recall Yahoo Finance Video
11:25AM  This Lung Cancer Drug Could Let Patients Forgo ChemoAnd Its Sending Mercks Stock Soaring Fortune
11:04AM  Novartis expands with acquisition, Viacom/CBS talks continue, Tesla issues recall Yahoo Finance
Apr-08-18 11:50AM  Here's Why Nektar Therapeutics Jumped 23% Higher in March Motley Fool
Apr-07-18 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline BMY Business Wire
Apr-06-18 03:59PM  How a Biotech Bummer Sent Nektar Therapeutics Stock South Today Motley Fool
01:16PM  Biotech Investors Should Consider The Four Horsemen Forbes
06:00AM  Cancer killer: Tampas best-kept secret M2Gen collects data from labs and bedsides to help target treatments American City Business Journals
12:26AM  [$$] Melanoma trial failure deals heavy blow to immunotherapy hopes Financial Times
Apr-05-18 05:20PM  Bristol-Myers Squibb Company Reminder: Important April 10, 2018 Lead Plaintiff Deadline in Class Action BMY ACCESSWIRE
04:33PM  BMY UPCOMING DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018 ACCESSWIRE
08:47AM  Merck shares rise after Barclays upgrades shares, downgrades competitor Pfizer CNBC
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool
05:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline - BMY ACCESSWIRE
02:04PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb Company And Encourages Investors With Losses To Contact The Firm ACCESSWIRE
Apr-02-18 04:30PM  Bristol-Myers Squibb to Hold Investor Event to Discuss AACR Highlights Business Wire
02:00PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Bristol-Myers Squibb Company Shareholders of a Class Action and a Lead Plaintiff Deadline of April 10, 2018 - BMY ACCESSWIRE
11:20AM  APRIL 10 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb Company And Encourages Investors With Losses To Contact The Firm ACCESSWIRE
Apr-01-18 07:00PM  The Lab Tests Behind Immuno-Oncology: Precise Enough? Forbes
06:00AM  FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Bristol-Myers Squibb Company to Contact the Firm Business Wire
Mar-31-18 07:11AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline BMY ACCESSWIRE
Mar-30-18 08:18AM  Do drug prices affect CEO pay? Faith-based investor group wants to know MarketWatch
Mar-29-18 02:42PM  Bristol-Myers Squibb Stock Shareholder Alert - Kehoe Law Firm, P.C. Investigating PR Newswire
07:23AM  The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen Zacks
Mar-28-18 02:50PM  The Klein Law Firm Reminds Investors of a Class Action on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY) GlobeNewswire
12:54PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline BMY Business Wire
11:04AM  FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy Zacks
07:43AM  The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, Bristol-Myers, Estee Lauder and Travelers Zacks
Mar-27-18 10:00PM  Roche Takes Aim at Bristol-Myers Squibb and Merck & Co. Motley Fool
04:42PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Bristol-Myers Squibb Company of a Class Action and a Lead Plaintiff Deadline of April 10, 2018 - BMY ACCESSWIRE
03:35PM  Top Stock Reports for Boeing, Texas Instruments & Bristol-Myers Zacks
06:59AM  U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibbs Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for Previously Treated Patients with MSI-H or dMMR Metastatic Colorectal Cancer for Priority Review Business Wire
Mar-26-18 05:15PM  BMY INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Bristol-Myers Squibb Company Investors and Encourages Investors to Contact the Firm Business Wire
03:16PM  Corp. Profitability Hits Highs on Tax Cuts: Goldman Investopedia
09:33AM  Goldman: Corporate profitability to jump to highest in 11 years because of tax cut CNBC
08:56AM  Stocks to open higher as USChina tensions cool down Yahoo Finance
07:20AM  Yahoo Finance Live: Market Movers - Mar 26, 2018 Yahoo Finance Video
06:59AM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma Business Wire
02:23AM  Roche's Tecentriq cocktail notches another lung cancer success Reuters
Mar-23-18 05:05PM  BMY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018 GlobeNewswire
04:26PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline BMY ACCESSWIRE
Mar-22-18 03:00PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Bristol-Myers Squibb Company of a Class Action and a Lead Plaintiff Deadline of April 10, 2018 BMY GlobeNewswire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM